Instil Bio, based in Dallas, Texas, develops autologous tumor infiltrating lymphocyte therapies for cancer and went public on March 19, 2021. Its lead product candidate, ITIL-306, targets folate receptor alpha in solid tumors.
Sandeep Laumas sold 30,000 shares of TIL on 10 September at $23.88 per share, worth a total of $716K. They now own 12,461 TIL shares, or a 100% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
